Literature DB >> 19857113

Phage displayed scFv: pIII scaffold may fine tune binding specificity.

Pooja Goswami1, Deepti Saini, Subrata Sinha.   

Abstract

The fine specificity of antibodies is important for their discriminating powers during diagnostics and in vivo therapy. We have attempted to isolate human scFv antibodies to the oncofetal antigen, the placental isozyme of alkaline phosphatase (PLAP) in which it is important to distinguish between the closely related intestinal alkaline phosphatase (IAP) and bone alkaline phosphatase (BAP) isozymes. As the antibodies are selected in the phage displayed form and might be finally used as different entities, including the soluble scFv form, it may be important to look at the influence of scaffolds in determining specificity. There have been earlier reports of the role of the constant region and other scaffolding proteins in determining specificity. In this paper, we report isolation of one such clone, E6, which showed specificity to PLAP in phage antibody form but lost the specificity when soluble scFv was tested for same, and showed partial cross reactivity to BAP. We suggest that the altered specificity of scFv might be the result of loss of phage pIII scaffold, which is present in phage-displayed antibody and may help the displayed antibody to assume specific conformational structure, which may govern binding characteristics of the same.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19857113     DOI: 10.1089/hyb.2009.0008

Source DB:  PubMed          Journal:  Hybridoma (Larchmt)        ISSN: 1554-0014


  2 in total

1.  Altered specificity of single-chain antibody fragments bound to pandemic H1N1-2009 influenza virus after conversion of the phage-bound to the soluble form.

Authors:  Yoshihiro Kaku; Akira Noguchi; Akiko Okutani; Satoshi Inoue; Kiyoshi Tanabayashi; Yoshie Yamamoto; Akitoyo Hotta; Michio Suzuki; Naoko Sugiura; Akio Yamada
Journal:  BMC Res Notes       Date:  2012-09-04

2.  The Use of Phage Display and Yeast Based Expression System for the Development of a Von Willebrand Factor Propeptide Assay: Development of a Von Willebrand Factor Propeptide Assay.

Authors:  S M Meiring; B D P Setlai; C Theron; R Bragg
Journal:  Biomed Res Int       Date:  2018-05-24       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.